Current state of the hybridoma technology

Liise-anne Pirofski, A. Casadevall, L. Rodriguez, L. S. Zuckier, Matthew D. Scharff

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The first description of the hybridoma technology in 1975 seemed to hold enormous promise for the treatment of a variety of human diseases. The ability to produce monoclonal antibodies led to the availability of large amounts of homogeneous and predictable preparations of antibody. The potential to renew indefinitely a particular antibody surmounted many of the technical and regulatory problems that made polyclonal antisera difficult to use as therapeutic agents in man. The hybridoma technology seemed even more valuable as it became clear that it could lead to the generation of pure, highly specific antibodies from impure, poorly characterized antigens. Monoclonal antibodies have been extremely useful in basic investigations and have facilitated the development of new diagnostic tests for serum and tissue components and infectious agents. However, novel approaches are needed in order to provide more useful, less immunogenic antibodies which could be used routinely for passive immunization in the treatment of infections or for tumor targeting.

Original languageEnglish (US)
JournalJournal of Clinical Immunology
Volume10
Issue number6 Supplement
DOIs
StatePublished - Nov 1990

Fingerprint

Hybridomas
Technology
Antibodies
Monoclonal Antibodies
Passive Immunization
Therapeutic Uses
Routine Diagnostic Tests
Immune Sera
Antigens
Therapeutics
Infection
Serum
Neoplasms

Keywords

  • Hybridomas
  • hyperchimeras
  • monoclonal antibody

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Current state of the hybridoma technology. / Pirofski, Liise-anne; Casadevall, A.; Rodriguez, L.; Zuckier, L. S.; Scharff, Matthew D.

In: Journal of Clinical Immunology, Vol. 10, No. 6 Supplement, 11.1990.

Research output: Contribution to journalArticle

Pirofski, Liise-anne ; Casadevall, A. ; Rodriguez, L. ; Zuckier, L. S. ; Scharff, Matthew D. / Current state of the hybridoma technology. In: Journal of Clinical Immunology. 1990 ; Vol. 10, No. 6 Supplement.
@article{9823a00fbd0d4d4599088c255257dbb1,
title = "Current state of the hybridoma technology",
abstract = "The first description of the hybridoma technology in 1975 seemed to hold enormous promise for the treatment of a variety of human diseases. The ability to produce monoclonal antibodies led to the availability of large amounts of homogeneous and predictable preparations of antibody. The potential to renew indefinitely a particular antibody surmounted many of the technical and regulatory problems that made polyclonal antisera difficult to use as therapeutic agents in man. The hybridoma technology seemed even more valuable as it became clear that it could lead to the generation of pure, highly specific antibodies from impure, poorly characterized antigens. Monoclonal antibodies have been extremely useful in basic investigations and have facilitated the development of new diagnostic tests for serum and tissue components and infectious agents. However, novel approaches are needed in order to provide more useful, less immunogenic antibodies which could be used routinely for passive immunization in the treatment of infections or for tumor targeting.",
keywords = "Hybridomas, hyperchimeras, monoclonal antibody",
author = "Liise-anne Pirofski and A. Casadevall and L. Rodriguez and Zuckier, {L. S.} and Scharff, {Matthew D.}",
year = "1990",
month = "11",
doi = "10.1007/BF00918686",
language = "English (US)",
volume = "10",
journal = "Journal of Clinical Immunology",
issn = "0271-9142",
publisher = "Springer New York",
number = "6 Supplement",

}

TY - JOUR

T1 - Current state of the hybridoma technology

AU - Pirofski, Liise-anne

AU - Casadevall, A.

AU - Rodriguez, L.

AU - Zuckier, L. S.

AU - Scharff, Matthew D.

PY - 1990/11

Y1 - 1990/11

N2 - The first description of the hybridoma technology in 1975 seemed to hold enormous promise for the treatment of a variety of human diseases. The ability to produce monoclonal antibodies led to the availability of large amounts of homogeneous and predictable preparations of antibody. The potential to renew indefinitely a particular antibody surmounted many of the technical and regulatory problems that made polyclonal antisera difficult to use as therapeutic agents in man. The hybridoma technology seemed even more valuable as it became clear that it could lead to the generation of pure, highly specific antibodies from impure, poorly characterized antigens. Monoclonal antibodies have been extremely useful in basic investigations and have facilitated the development of new diagnostic tests for serum and tissue components and infectious agents. However, novel approaches are needed in order to provide more useful, less immunogenic antibodies which could be used routinely for passive immunization in the treatment of infections or for tumor targeting.

AB - The first description of the hybridoma technology in 1975 seemed to hold enormous promise for the treatment of a variety of human diseases. The ability to produce monoclonal antibodies led to the availability of large amounts of homogeneous and predictable preparations of antibody. The potential to renew indefinitely a particular antibody surmounted many of the technical and regulatory problems that made polyclonal antisera difficult to use as therapeutic agents in man. The hybridoma technology seemed even more valuable as it became clear that it could lead to the generation of pure, highly specific antibodies from impure, poorly characterized antigens. Monoclonal antibodies have been extremely useful in basic investigations and have facilitated the development of new diagnostic tests for serum and tissue components and infectious agents. However, novel approaches are needed in order to provide more useful, less immunogenic antibodies which could be used routinely for passive immunization in the treatment of infections or for tumor targeting.

KW - Hybridomas

KW - hyperchimeras

KW - monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=0025649050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025649050&partnerID=8YFLogxK

U2 - 10.1007/BF00918686

DO - 10.1007/BF00918686

M3 - Article

VL - 10

JO - Journal of Clinical Immunology

JF - Journal of Clinical Immunology

SN - 0271-9142

IS - 6 Supplement

ER -